The effect of ivabradine therapy on heart failure patients with reduced ejection fraction: a systematic review and meta-analysis

International Journal of Clinical Pharmacy
Camila HartmannCristina Pellegrino Baena

Abstract

Background Ivabradine is currently indicated to lower heart rate in Heart Failure with Reduced Ejection Fraction (HFrEF) patients. However its effect apart from beta-blockers is not clear. Aim of the review To study the additional effect of ivabradine, apart from the effect of beta-blockers, on cardiovascular death, all-cause mortality, hospitalization due to HF and heart rate in HFrEF population. Method Electronic searches were conducted up to June 2016 to include randomized controlled trials where ivabradine was compared to a control group. Relative risks RRs and their 95% confidence intervals (CI 95%) were pooled and the random and fixed effect were used to summarize the results according to heterogeneity levels. Heterogeneity among studies was measured by the I-squared statistic Results Of 1790 studies, seven met the inclusion criteria for the systematic review and meta-analysis. The population consisted of 17,747 patients. Risk of bias was generally high for beta-blocker doses lower than recommended. Interventions lasted 1.5-22.9 months and pooled relative risks RR (95%) for all-cause mortality, cardiovascular death and hospitalization for HF were 0.98 (0.90-1.06); 0.99 (0.91-1.08); and 0.87 (0.68-1.12) respectively. Heart...Continue Reading

References

Feb 26, 2000·Journal of Internal Medicine·A ReunanenA Aromaa
Jun 2, 2001·The New England Journal of Medicine·M PackerUNKNOWN Carvedilol Prospective Randomized Cumulative Survival Study Group
Jun 3, 2009·Annals of Internal Medicine·Finlay A McAlisterPaul W Armstrong
Jul 23, 2009·Annals of Internal Medicine·David MoherUNKNOWN PRISMA Group
Jul 19, 2011·International Journal of Cardiology·Maurizio VolterraniGiuseppe M C Rosano
Jun 12, 2013·Journal of the American College of Cardiology·Clyde W YancyUNKNOWN American Heart Association Task Force on Practice Guidelines
Mar 14, 2014·JACC. Heart Failure·Eugene Braunwald
Sep 2, 2014·The New England Journal of Medicine·Kim FoxUNKNOWN SIGNIFY Investigators
Sep 20, 2015·Journal of Clinical Epidemiology·Ana C AlbaGordon H Guyatt
Jan 15, 2016·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TsutsuiUNKNOWN study investigators
Feb 3, 2016·Current Treatment Options in Cardiovascular Medicine·Takeshi Kitai, W H Wilson Tang
Sep 30, 2017·Journal of the American College of Cardiology·Jacob S KoruthSrinivas R Dukkipati
Apr 25, 2018·Heart Failure Reviews·Dario GrandeNadia Aspromonte

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.